University of Minnesota

Leland Stanford Junior University

Aleta Biotherapeutics Inc.

Benjamin Joseph Hackel

Sanjiv Sam Gambhir

Lawrence Arthur Stern

Paul David Rennert

Roy R Lobb

Carston R Wagner

Zhen Cheng

Richard H Kimura

Frederick T Chin

Bin Shen

Juergen Karl Willmann

Yiannis J Kaznessis

Arutselvan Natarajan

Sumit Bhatnagar

Lotfi Abou-Elkacem

Clifford Csizmar

Hong Zhou

Patrick Samuel Lown

Rakesh Kumar Bam

Seth Ritter

Justin Klesmith

Amelie Margarete Marianne Lutz

Max Anthony Kruziki

Robert Teed

Affibody polypeptides that specifically bind to B7-H3 are provided. Exemplary anti-B7-H3 affibodies are provided. The affibody polypeptides specifically recognize and bind to B7-H3 with high affinity. The affibodies can be conjugated to contrast agents, including without limitation microbubbles for contrast-enhanced ultrasound imaging

Affibody proteins specific for B7-H3 (CD276)

Provided herein are a vector, a genetically modified bacterium including the vector, methods of making the bacterium, methods of using the bacterium, and kits including the bacterium. The vector includes a coding region encoding at least one antimicrobial peptide, and the antimicrobial peptide includes at least one lysin.

Vectors, genetically modified bacteria, and methods of making and using

CD19 variants, methods of identifying CD19 variants, and methods of using such CD19 variants, e.g., for treating cancer, are described.

CD19 variants

Certain embodiments of the invention provide epithelial cell adhesion molecule (EpCAM) binding polypeptides, as well as conjugates and CSANs comprising such polypeptides. Additionally, certain embodiments of the invention also provide methods of using such polypeptides and compounds for molecular imaging and molecularly targeted therapies.

EpCAM targeted polypeptides, conjugates thereof, and methods of use thereof

This disclosure describes non-naturally occurring protein scaffolds and methods of making and using the protein scaffolds. In one aspect, therefore, this disclosure describes a non-naturally occurring protein scaffold that includes a plurality of structural domains and a plurality of loop regions that include an amino acid sequence that varies from a naturally-occurring loop region by at least one amino acid deletion, substitution, or addition. Generally, the structural domain or domains can include at least one &#x3b2; structure and/or at least one a helix.

Protein scaffolds and methods of use

Embodiments of the present disclosure provide for labeled probes such as aCu-FN3 probe (FN3 refers to fibronectin type 3 domain); methods of making labeled probes; pharmaceutical compositions including labeled probes; methods of using labeled probes; methods of diagnosing, localizing, monitoring, and/or assessing non-Hodgkin's lymphoma, cancers, tumors, precancerous cells, and related biological events using labeled probes; kits for diagnosing, localizing, monitoring, and/or assessing non-Hodgkin's lymphoma, cancers, tumors, precancerous cells, and related biological events; and the like.

Probes and methods of imaging non-Hodgkins lymphoma

Disclosed are peptides comprising a molecular scaffold portion and a loop portion that binds to integrin &#x3b1;&#x3b2;. This integrin is expressed on pancreatic tumors, making the peptides useful as imaging agents, among other uses. The peptides showed single-digit nanomolar dissociation constants similar to antibodies used clinically for imaging and therapy. The peptides rapidly accumulated in &#x3b1;&#x3b2;-positive tumors, which led to excellent tumor-to-normal contrast. The peptides are specific for the targeted integrin &#x3b1;&#x3b2;receptors expressed on orthotopic pancreatic tumors and various xenografts used. Additionally, pharmacokinetic-stabilization strategies endowed knots with rapid renal clearance, which significantly reduced off-target dosing.

Cystine knot peptides that bind alpha-V-beta-6 integrin

Growing community of inventors

Edina, MN, United States of America

Benjamin Joseph Hackel